ENANTA PHARMACEUTICALS INC (ENTA)

US29251M1062 - Common Stock

12.37  -0.11 (-0.88%)

After market: 12.37 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
97.1M
-20.73%		86.2M
-11.23%		79.2M
-8.12%		69.174M
-12.66%
EBITDA
YoY % growth
-106.27M
-179.95%		-120.83M
-13.70%		-134.83M
-11.59%		-113.22M
16.03%		N/AN/AN/AN/A
EBIT
YoY % growth
-109.6M
-163.46%		-123.8M
-12.96%		-137.2M
-10.82%		-108.392M
21.00%
Operating Margin
-112.87%-143.62%-173.23%-156.69%
EPS
YoY % growth
-3.91
-114.84%		-5.91
-51.15%		-6.37
-7.78%		-5.19
18.53%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		-1.36
24.07%
Revenue
Q2Q % growth		16.853M
-5.32%
EBITDA
Q2Q % growth		-32.64MN/AN/AN/AN/A
EBIT
Q2Q % growth		-27.516M
30.25%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2024
Q2Q % growth		 -1.58
-13.67%		-1.22-0.36-29.73%
Q4 2023
Q2Q % growth		 -1.33
-4.72%		-2.190.8639.26%
Q3 2023
Q2Q % growth		 -1.86
-21.57%		-2.380.5221.99%
Q2 2023
Q2Q % growth		 -1.79
-9.82%		-2.020.2311.37%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2024
Q2Q % growth		 18.003M
-23.68%		21.708M-3.705M-17.07%
Q4 2023
Q2Q % growth		 18.93M
-6.84%		17.848M1.082M6.06%
Q3 2023
Q2Q % growth		 18.89M
-3.03%		18.419M471K2.56%
Q2 2023
Q2Q % growth		 17.8M
-4.91%		19.566M-1.766M-9.03%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -7.03% 0% 1.29%
Revenue0% -1.02% 0% -6.34%